acetylcysteine oral / Generic mfg. - LARVOL DELTA

Neuroprotective effects of plasma-activated N-acetylcysteine against streptozotocin-induced behavioral deficits in rats: Attenuation of oxidative stress and cholinergic dysfunction. (PubMed, Ecotoxicol Environ Saf) - "At the transcriptional level, PAN upregulated α7 nAChR, Nrf2 and BDNF expression while downregulating AChE and Keap1. Collectively, these findings suggest that PAN mitigates behavioral impairments in the icv-STZ rat model of Alzheimer's disease, potentially through attenuation of oxidative stress and restoration of cholinergic neurotransmission."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Mood Disorders • Pain • Psychiatry • ACHE • BDNF • KEAP1

Overlapping Hepatic and Neurological Toxicity Following Intentional Multidrug Poisoning with Acetaminophen, Metoclopramide, and Metronidazole: A Case Report. (PubMed, Clin Med Insights Case Rep) - "Management included oral N-acetylcysteine for APAP toxicity, intravenous diphenhydramine and diazepam for extrapyramidal symptoms, supportive ICU care, and psychiatric intervention. Rapid identification and agent-specific management, including NAC for APAP, symptomatic therapy for metoclopramide and metronidazole toxicity, and supportive care, resulted in full recovery without long-term sequelae. Emergency clinicians should maintain high suspicion for multiple co-ingestants and use targeted interventions to optimize outcomes."

Journal • Ataxia • Hematological Disorders • Movement Disorders • Psychiatry

Effects of topically applied liquid N-acetylcysteine for the management of burning mouth syndrome. (PubMed, Sci Rep) - "Topically administered liquid NAC demonstrates potential as an effective and well-tolerated therapeutic strategy for managing BMS, offering symptom relief with minimal systemic burden. Although the combination with clonazepam did not demonstrate sustained superiority at 8 weeks, its principal advantage is a faster onset of improvement in OHIP‑14 K, evident by week 4."

Clinical • Journal • Neuralgia • Pain

Protocol for NAC Attack, a phase-3, multicenter randomized, parallel, double masked, placebo controlled trial evaluating the efficacy and safety of oral N-acetylcysteine (NAC) in patients with retinitis pigmentosa. (PubMed, medRxiv) - P3 | "Therefore, the trial is of high public health, clinical, and scientific significances. The ClinicalTrials.gov ID for NAC Attack is NCT05537220 ."

Clinical • Journal • P3 data • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Inhaled Relief: Rethinking Mucolytics with Nebulized N-Acetylcysteine (APSR 2025) - "Post-antibiotic treatment, while his systemic symptoms resolved, he continued to experience significant respiratory distress due to thick tracheostomy secretions despite treatment with nebulized 0.9% and 3% saline and oral N- acetylcysteine (NAC). Nebulized NAC may be considered a valuable adjunct in palliative or supportive care settings to improve airway clearance and patient comfort. Further studies are needed to establish standardized protocols and assess broader efficacy."

Acute Kidney Injury • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Hematological Malignancies • Hypertension • Infectious Disease • Lymphoma • Metabolic Disorders • Nephrology • Palliative care • Peripheral T-cell Lymphoma • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • Septic Shock • T Cell Non-Hodgkin Lymphoma

Glutathione deficiency and disturbances of sulfur homeostasis in the pathophysiology of schizophrenia (PubMed, Postepy Biochem) - "In one of the recently developed rat’s neurodevelopmental model, schizophrenic-like changes were induced by administration of buthioninesulfoximine (BSO) - an inhibitor of glutathione synthesis and a dopamine reuptake inhibitor - the compound GBR 12909 during the developmental period...The usefulness of the developed model was tested by the effect of the antipsychotic drug aripiprazole and N-acetylcysteine...At the biochemical level, both drugs significantly reduced the elevated concentration of bound sulfane sulfur in the hippocampus of model rats. Recent studies indicate that in the neurodevelopmental pathophysiology of schizophrenia, disturbances in the homeostasis of sulfur compounds play an important role, which are corrected by the action of drugs."

Journal • Review • CNS Disorders • Psychiatry • Schizophrenia

The Effectiveness and Safety of Oral N-Acetylcysteine in Combination With Narrow-Band Ultraviolet B (NB-UVB) Phototherapy Compared With NB-UVB Phototherapy Alone in the Treatment of Vitiligo: A Pilot Study. (PubMed, Health Sci Rep) - "Oral NAC appears to be a safe adjuvant therapy in the treatment of generalized vitiligo patients in combination with NB-UVB phototherapy. "Evaluation of the efficacy of NB-UVB phototherapy with oral N- acetylcysteine compared with NB-UVB phototherapy alone in the treatment of vitiligo patients: a randomized controlled clinical trial".Clinical trial registration number: IRCT20210729052013N1."

Clinical • Journal • Dermatology • Immunology • Vitiligo

Oral N-Acetylcysteine in Hepatitis C-Induced Acute Liver Injury: A Case Report (ACG 2025) - "This case highlights a patient with chronic liver diseases of HCV and non-alcoholic fatty liver disease (NAFLD) who was started on oral NAC in the setting of non-acetaminophen liver failure.Case Description/ A 54-year-old male with a past medical history of HCV (previously treated/sustained virological response), NAFLD, and recent cocaine/methamphetamine use presented with cough and markedly elevated transaminases (AST 778, ALT 1069). Oral NAC may benefit select patients with HCV and acute liver injury, particularly when IV formulations are unavailable or contraindicated. Further studies are needed to define optimal dosing, timing, and patient selection."

Case report • Clinical • Cough • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Dysfunction-Associated Steatotic Liver Disease • Respiratory Diseases

Rescue with Redox: An Underutilized Therapeutic Attempt in Antitubercular Therapy-Induced Liver Injury (ACG 2025) - "We present the first adult case demonstrating rapid biochemical reversal of severe AT-DILI using intravenous glutathione(GSH) after oral N-acetylcysteine (NAC) failure, averting liver transplantation.Case Description/ A 35-year-old male with active pulmonary tuberculosis developed jaundice, pruritus, and coagulopathy with an International Normalized Ratio(INR) of 7.55 and a Model for End-Stage Liver Disease(MELD) score of 34 one month after initiating the first-line antitubercular therapy. Aldini G et al. Free Radic Res 2018; 52(7):751–62"

Dermatology • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Pruritus • Respiratory Diseases • Tuberculosis

Association between early administration of mucoactive agents and in-hospital mortality in patients with pneumonia requiring mechanical ventilation: a nationwide cohort study. (PubMed, J Intensive Care) - "In patients with ventilated pneumonia, early administration of mucoactive agents was associated with lower in-hospital mortality."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Onychotillomania Dentata: A Newly Defined Oral-Induced Pattern of Repetitive Nail Trauma. (PubMed, Skin Appendage Disord) - "Oral n-acetylcysteine (600 mg every 12 h) was prescribed as adjunctive therapy. Additionally, chronic mechanical friction may pose a risk of dental damage, including enamel erosion. Management involves behavioral modification strategies, pharmacologic support when appropriate, and interdisciplinary psychodermatologic care."

Journal • Behavior Disorders • Dermatology • Mental Retardation • Mood Disorders • Pediatrics • Psychiatry

Oral acetylcysteine and the risk of age-related macular degeneration: A retrospective cohort study. (PubMed, Ophthalmology) - "NAC use was associated with a significantly reduced risk of AMD, especially dry AMD. These findings support the need for further investigation into the effectiveness of NAC as a preventive treatment for AMD."

Journal • Retrospective data • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=483 | Active, not recruiting | Sponsor: Johns Hopkins University | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

The effectiveness and safety of Oral N-acetylcysteine in combination with Narrow-Band Ultraviolet B (NB-UVB) Phototherapy compared with NB-UVB Phototherapy alone in the treatment of Vitiligo: A Pilot study (EADV 2025) - "Oral NAC can be used as a safe supportive therapy in the treatment of generalized vitiligo patients in combination with NB-UVB phototherapy."

Clinical • Combination therapy • Dermatology • Immunology • Vitiligo

N-Acetyl-Cysteine for Treatment of AGA in Men (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: Kafrelsheikh University | Unknown status ➔ Completed

Trial completion • Alopecia • Dermatology • Immunology

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=483 | Enrolling by invitation | Sponsor: Johns Hopkins University | Active, not recruiting ➔ Enrolling by invitation

Enrollment open • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

IRANNACPD: Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study (clinicaltrials.gov) - P2 | N=42 | Completed | Sponsor: Kurdistan University of Medical Sciences

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=483 | Active, not recruiting | Sponsor: Johns Hopkins University | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Protective effects of Aloe vera extract against doxorubicin-induced degeneration in ovarian follicles and stromal cells in mice. (PubMed, Braz J Med Biol Res) - "The positive control group mice received pretreatment of N-acetylcysteine orally (po), followed by a single intraperitoneal (ip) dose of DOX after 1 h (NAC+DOX). Furthermore, 0.1 and 1.0 mg/kg Aloe vera reduced TNF-α protein expression and increased NRF2, SOD, and CAT mRNA levels. In conclusion, 0.1 and 1.0 mg/kg Aloe vera had protective effects against DOX-induced degeneration in ovarian follicles and stromal cells in mice."

Journal • Preclinical • Oncology • CAT • TNFA

PREEMPTIVE TMP-SMX/N-ACETYLCYSTEINE PROPHYLAXIS MITIGATES THE INCIDENCE OF INTERSTITIAL PNEUMONIA IN DLBCL IMMUNOCHEMOTHERAPY: A DUAL-CENTER COHORT STUDY ON RISK STRATIFICATION AND CLINICAL OUTCOMES (EHA 2025) - "Background: Interstitial pneumonia (IP) is a common and potentially life-threatening complication in newly diagnosed CD20-positive diffuse large B-cell lymphoma () patients receiving rituximab-based immunochemotherapy. The effectiveness of prophylactic use of trimethoprim-sulfamethoxazole (TMP-SMX), either alone or in combination with N-acetylcysteine effervescent tablets, in reducing the risk of IP remains unclear and warrants further investigation... In this cohort of newly diagnosed patients, interstitial pneumonia (IP) occurred in 22.8% of cases, with pre-existing pulmonary disease (adjusted HR=3.12, 95% CI=1.89-5.14) and absence of TMP-SMX prophylaxis (HR=2.98, 95% CI=1.72-5.16) identified as key modifiable risk factors. Crucially, dual prophylaxis with TMP-SMX and N-acetylcysteine reduced IP incidence by 86% compared to untreated controls (ARR=19.7%, P<0.001). Lenalidomide-based regimens independently increased IP risk (HR=2.31, 95% CI=1.45-3.67), underscoring..."

Clinical • Clinical data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Interstitial Lung Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • CD20

Medication Development for Cannabis Use Disorder and Cannabis Withdrawal (CPDD 2025) - "First, a 12-week randomized controlled trial found significant reductions in cannabis use outcomes with varenicline treatment combined with medical management compared to placebo treatment...Second, treatment-seeking youth with CUD were randomized to receive a double-blind 12-week course of oral N-acetylcysteine (NAC) 1200 mg or placebo twice daily; all received weekly medical management and brief behavioral counseling. No difference in cannabis use reduction or cessation outcomes was noted between participants in the NAC and placebo groups, suggesting that NAC is not efficacious for youth CUD when not paired with contingency management. Finally, a phase 2 randomized multi-center double-blind, multiple dose, placebo-controlled clinical trial demonstrated that a unique 34-day taper/titration with nabilone and gabapentin (PP-01) significantly mitigated withdrawal symptoms and decreased cannabis use compared to placebo in adults with moderate to severe CUD seeking to..."

Substance Abuse

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=483 | Recruiting | Sponsor: Johns Hopkins University | Trial completion date: Dec 2028 ➔ May 2029 | Trial primary completion date: Dec 2028 ➔ May 2029

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Efficacy, Safety, and Cost-Effectiveness of N-Acetylcysteine in Preventing Amphotericin B Nephrotoxicity in Egyptian Patients with Hematological Malignancies: A Randomized Controlled Trial. (PubMed, Hosp Pharm) - P=N/A | "This study evaluated the efficacy, safety, and cost-effectiveness of oral N-acetylcysteine (NAC) in preventing AmB-d nephrotoxicity and promoting renal recovery in Egyptian hematological malignancy patients. The favorable NNT for renal recovery suggests clinical relevance, warranting further investigation in larger studies. Trial registration: ClinicalTrials.gov identifier, NCT06122311."

HEOR • Journal • Acute Kidney Injury • Hematological Disorders • Hematological Malignancies • Infectious Disease • Nephrology • Oncology • Renal Disease

N-acetylcysteine enhances the antipsychotic effect of aripiprazole in the neurodevelopmental rat model of schizophrenia. (PubMed, Pharmacol Biochem Behav) - "The schizophrenia-like behavior was induced in Sprague-Dawley male pups in the neonatal days p5-p16 by repeated administration of the glutathione synthesis inhibitor L-butionine-(S,R)-sulfoximine (BSO) given together with the dopamine reuptake inhibitor 1-[2-[Bis-4(fluorophenyl)methoxy]ethyl]-4-3-(3-phenylpropyl) (GBR 12909)...Moreover, repeated co-treatment with low doses of ARI with NAC also reversed schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. The above results indicated that NAC enhanced the action of ARI in the used neurodevelopmental rat model of schizophrenia, and the mechanism of action of the used drugs in this model is discussed."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Incidence and predictors of linezolid-associated thrombocytopenia in critically Ill patients: nomogram development based on comprehensive screening of over 70 factors. (PubMed, Expert Rev Anti Infect Ther) - "Protective factors were surgery (OR 0.34, p < 0.01), IV N-acetylcysteine (OR 0.12, p < 0.01), oral N-acetylcysteine (OR 0.17, p < 0.01), higher baseline platelets (OR 0.79, p = 0.05), and acetaminophen (OR 0.42, p < 0.01)...Prolonged therapy, solid organ tumors, dialysis, high lactate, and vasopressor use increase risk; high platelet counts, N-acetylcysteine, and IV acetaminophen decrease risk. External validation and prospective trials are warranted."

Journal • Critical care • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia